C4 Therapeutics (CCCC) AI Stock Analysis

• Market Cap: $246.16M
• Dividend Yield: N/A
• Average Volume (3M): 1.49M
• Price to Earnings (P/E): ―
• Beta (1Y): 3.45
• Revenue Growth: -10.57%
• EPS Growth: 1.98%
• Country: US
• Employees: 110
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.44
• Shares Outstanding: 96,914,420
• 10 Day Avg. Volume: 1,656,370
• 30 Day Avg. Volume: 1,487,175
• PEG Ratio: 0.06
• Price to Book (P/B): 1.16
• Price to Sales (P/S): 7.02
• P/FCF Ratio: -3.82
• Enterprise Value/Market Cap: 0.12
• Enterprise Value/Revenue: 1.02
• Enterprise Value/Gross Profit: 1.08
• Enterprise Value/Ebitda: -0.25
• 1Y Price Target: $8.67
• Price Target Upside: 251.01% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -1.51
• Revenue Forecast (FY): $31.47M

• Rating: 56 Neutral
• Price Target: $2.50 ▲(1.21% Upside)

C4 Therapeutics' overall stock score is primarily influenced by its financial challenges, which weigh heavily on the score. However, positive corporate events, including strategic partnerships and promising trial results, provide a boost. Technical indicators show moderate strength, but valuation concerns due to negative earnings remain a significant risk.

Positive Factors

Strategic Partnerships

The partnership with Pfizer enhances C4 Therapeutics' clinical trial capabilities, leveraging Pfizer's resources and expertise, which could accelerate drug development and improve treatment options for multiple myeloma.

Cash Runway Extension

The stock and warrants offering extends C4 Therapeutics' cash runway to 2028, providing financial stability and enabling continued investment in R&D and clinical trials without immediate funding pressures.

Promising Clinical Trial Results

Positive Phase 1 trial results for cemsidomide indicate potential efficacy and safety, supporting further development and enhancing C4 Therapeutics' pipeline strength in addressing unmet medical needs.

Negative Factors

Negative Cash Flow

Negative operating and free cash flows highlight inefficiencies in cash management, posing risks to financial sustainability and limiting flexibility for strategic investments.

Profitability Challenges

Ongoing losses and negative margins indicate operational challenges, necessitating improvements in cost management and revenue generation to achieve sustainable profitability.

Revenue Decline

A decline in revenue growth suggests challenges in market penetration or product adoption, potentially impacting long-term growth prospects and necessitating strategic adjustments.

C4 Therapeutics Business Overview & Revenue Model

Company Description

C4 Therapeutics (CCCC) is a biotechnology company focused on developing innovative therapeutics that harness the power of targeted protein degradation to treat cancer and other diseases. The company operates within the biopharmaceutical sector, leveraging its proprietary platform to create a pipeline of drug candidates designed to selectively degrade disease-causing proteins. C4 Therapeutics aims to address unmet medical needs by providing more effective and safer treatment options for patients with various types of cancer.

How the Company Makes Money

C4 Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies that seek to leverage its proprietary protein degradation technology. The company may receive upfront payments, milestone payments tied to the achievement of specific development goals, and royalties on sales of products developed through these collaborations. Additionally, C4 Therapeutics may engage in grant funding or government contracts to support research and development efforts. The success of its revenue model is heavily reliant on the advancement of its drug candidates through clinical trials and their eventual commercialization in partnership with established pharmaceutical companies.

C4 Therapeutics Financial Statement Overview

Summary

C4 Therapeutics faces significant financial challenges, with persistent losses impacting profitability and cash flows. While the balance sheet remains relatively stable, the company needs to address its operational inefficiencies to improve financial health. Strategic adjustments may be necessary to enhance revenue generation and cost management to achieve sustainable growth.

Income Statement

The income statement reveals a company struggling with profitability. The TTM (Trailing-Twelve-Months) shows negative EBIT and net income, indicating operational challenges. Although there's a modest revenue growth of 11.8% from the previous year, margins remain negative, suggesting ongoing difficulties in cost management or revenue generation.

Balance Sheet

The balance sheet shows a reasonable equity ratio of 61.07%, indicating a solid capital structure with more assets funded by equity. However, the debt-to-equity ratio of 0.33 reflects manageable leverage but could pose risks if financial performance does not improve. Return on equity remains negative due to ongoing losses.

Cash Flow

Cash flow analysis indicates issues with cash generation, as both operating and free cash flows are negative in the TTM (Trailing-Twelve-Months). The operating cash flow to net income ratio is negative, pointing to inefficiencies in converting sales into cash, while free cash flow is deteriorating, signaling cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	30.11M	35.58M	20.76M	31.10M	45.78M	33.20M
Gross Profit	28.34M	35.58M	13.02M	31.10M	45.78M	-45.24M
EBITDA	-120.98M	-103.37M	-122.10M	-124.28M	-80.25M	-58.83M
Net Income	-119.08M	-105.32M	-132.49M	-128.18M	-83.89M	-66.33M
Balance Sheet
Total Assets	265.49M	349.60M	376.45M	430.84M	506.76M	400.14M
Cash, Cash Equivalents and Short-Term Investments	191.88M	244.90M	253.68M	276.15M	309.28M	371.69M
Total Debt	61.46M	65.76M	70.98M	87.15M	42.88M	22.92M
Total Liabilities	111.08M	133.62M	130.34M	141.61M	117.16M	119.35M
Stockholders Equity	154.41M	215.99M	246.11M	289.23M	389.61M	280.79M
Cash Flow
Free Cash Flow	-95.07M	-65.34M	-108.55M	-111.44M	-88.24M	-67.90M
Operating Cash Flow	-94.48M	-65.16M	-106.84M	-105.94M	-86.97M	-67.25M
Investing Cash Flow	85.80M	-51.27M	158.35M	58.42M	-189.34M	-190.50M
Financing Cash Flow	7.84M	45.34M	45.49M	1.15M	171.40M	348.93M

C4 Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.47
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Neutral. The current price of 2.47 is below the 20-day moving average (MA) of 2.54, above the 50-day MA of 2.45, and above the 200-day MA of 2.09, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 47.70 is Neutral, neither overbought nor oversold. The STOCH value of 27.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CCCC.

C4 Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CCCC	56 Neutral	$246.16M	―	-59.98%	―	-10.57%	1.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SLS	43 Neutral	$286.31M	―	-84.33%	―	―	59.04%
MCRB	42 Neutral	$155.24M	27.90	15.95%	―	448.44%	―
ELDN	35 Underperform	$127.64M	―	-95.49%	―	―	72.35%
TVGN	33 Underperform	$109.19M	-3.04	―	―	―	-234.46%

C4 Therapeutics Corporate Events

C4 Therapeutics Announces Stock and Warrants Offering

On October 16, 2025, C4 Therapeutics announced an underwritten offering of common stock and warrants, expected to close on October 17, 2025. The company anticipates net proceeds of approximately $117 million, extending its cash runway to the end of 2028, with potential total proceeds reaching $341.7 million if all warrants are exercised.

C4 Therapeutics Presents Phase 1 Trial Data

On October 16, 2025, C4 Therapeutics announced the presentation of data from its Phase 1 clinical trial of cemsidomide combined with dexamethasone for relapsed/refractory multiple myeloma, highlighting its potential efficacy and safety profile. Additionally, the company terminated a sales agreement prospectus with TD Securities, impacting its stock sale strategy, while maintaining the agreement’s validity for future use, having previously raised approximately $9.6 million through stock sales.

C4 Therapeutics Partners with Pfizer for Clinical Trial

On October 1, 2025, C4 Therapeutics announced a clinical trial collaboration and supply agreement with Pfizer. Under this agreement, Pfizer will provide elranatamab, a BCMAxCD3 bispecific antibody, at no cost for C4T’s upcoming Phase 1b trial. This trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab for treating relapsed/refractory multiple myeloma. The collaboration aims to establish an optimal dose for this combination therapy, potentially improving outcomes for multiple myeloma patients.

C4 Therapeutics Reports Promising Phase 1 Trial Results

On September 20, 2025, C4 Therapeutics announced data from its Phase 1 clinical trial of cemsidomide, an IKZF1/3 degrader, in combination with dexamethasone for relapsed/refractory multiple myeloma. The trial showed promising results with a 50% overall response rate at the highest dose level and a differentiated safety profile, supporting further development for potential accelerated approval. The company plans to initiate Phase 2 and Phase 1b studies in 2026, aiming to position cemsidomide as a class-leading treatment option.